The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels...

Full description

Bibliographic Details
Main Authors: Michaël J. B. van Baar, Annemarie B. van der Aart, Klaas Hoogenberg, Jaap A. Joles, Hiddo J. L. Heerspink, Daniël H. van Raalte
Format: Article
Language:English
Published: SAGE Publishing 2019-07-01
Series:Therapeutic Advances in Endocrinology and Metabolism
Online Access:https://doi.org/10.1177/2042018819865398

Similar Items

Similar Items